Tenjunct Trademark Details

This mark is dead with a status of Abandoned - No Statement of Use Filed. The last case file activity for this mark occured 9 years ago on Monday, April 6, 2015, according to the United State Patent & Trademark Office
Word Mark Tenjunct
Status Dead 606 — Abandoned - No Statement of Use Filed

Current Owner

Eli Lilly and Company of Indianapolis, IN

View all trademarks for Eli Lilly and Company
Other Trademarks for Eli Lilly and Company
Serial Number 85399320
Status Date Monday, April 6, 2015
Filing Date Monday, April 6, 2015
Attorney Bruce W. Longbottom

Correspondent

BRUCE W. LONGBOTTOM
ELI LILLY AND COMPANY
LILLY CORPORATE CENTER
INDIANAPOLIS, IN 46285-0001

Case File Statements

Goods & Services Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants

Classifications

International Class Codes
005 — Class 5 includes mainly pharmaceuticals and other preparations for medical or veterinary purposes.
U.S. Class Codes 006, 018, 044, 046, 051, 052
Status 6 — Active
Status Date Friday, August 19, 2011
Primary Code 005

You must be signed in to print.

Once signed in, look for the PDF button.